 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| ABSK061 / Abbisko, ABSK043 / Abbisko
Enrollment open, Metastases: A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov) - Nov 18, 2024
P2, N=202, Recruiting, Sponsor: Abbisko Therapeutics Co, Ltd
Not yet recruiting --> Recruiting
- ||||| ABSK061 / Abbisko, ABSK043 / Abbisko
New P2 trial, Metastases: A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov) - Oct 8, 2024
P2, N=202, Not yet recruiting, Sponsor: Abbisko Therapeutics Co, Ltd
- ||| ABSK061 / Abbisko
Enrollment open, Trial initiation date, Metastases: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 25, 2022
P1, N=85, Recruiting, Sponsor: Abbisko Therapeutics Co, Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
- ||| ABSK061 / Abbisko
New P1 trial, Metastases: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 17, 2022
P1, N=85, Not yet recruiting, Sponsor: Abbisko Therapeutics Co, Ltd